Navigation Links
Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology

CHICAGO and CARLSBAD, Calif., June 2 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that two of the Company's partnered oncology drugs were highlighted during the American Society of Clinical Oncology (ASCO) meeting. Data from both drugs highlighted positive activity that supports the continuation of clinical development, and both drugs were well tolerated up to very high doses. Results from Eli Lilly's Phase 1 clinical trial evaluating LY2181308 in patients with cancer and updated data from OncoGenex's Phase 2 trial evaluating OGX-011 in patients with hormone refractory prostate cancer (HRPC) were presented yesterday, June 1, at the annual ASCO meeting in Chicago. Both Lilly and OncoGenex are developing additional anticancer drugs discovered by Isis.

In both presentations, antisense drugs being developed by Isis' partners OncoGenex and Lilly continue to demonstrate the potential of antisense technology to treat multiple cancers. OncoGenex presented Phase 2 data on OGX-011 demonstrating better than expected survival results in combination with chemotherapy, reduction in levels of clusterin (the target of OGX-011), durable reductions in pain, and a decline in PSA, a protein that is often elevated in patients with prostate cancer. Encouraging data from this trial support initiation of registration trials required for product approval. OGX-011 was jointly discovered and is being co-developed by Isis and OncoGenex. Lilly presented first-in-human data from LY2181308 that showed the drug distributed to tumor cells with evidence of reduced survivin protein levels in tumor cells, LY2181308's target and one of the most commonly elevated proteins in cancer. Lilly has selected a dose of 750 mg/week of LY2181308 for Phase 2 studies where LY2181308 will be evaluated in combination with other oncology agents.

"The progress our partners are making with our antisense drugs demonstrate the potential of antisense technology to provide new, first-in-class treatment options to treat a variety of cancers. Antisense drugs are highly selective for their targets which minimizes the off target interactions that are responsible for so many toxicities observed with traditional drugs in oncology studies," said Brett Monia, Ph.D., Vice President of Drug Discovery Research at Isis Pharmaceuticals. "The encouraging safety profiles observed in both Lilly's and OncoGenex's studies support further clinical evaluation of both drugs."

OGX-011 and LY2181308 are part of Isis' cancer portfolio of first-in-class drugs, which act upon biological targets associated with cancer progression and/or treatment resistance. The distribution of antisense drugs to tumor cells and the high degree of specificity of these drugs to their target make them attractive new treatment options for a broad range of cancers.


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at

This press release includes forward-looking statements regarding Isis' business, its drug discovery and development pipeline, and the therapeutic potential of LY2181308 and OGX-011 for the treatment of cancer. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its quarterly report on Form 10-Q for the quarter ended March 31, 2008, which are on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
2. Briefing on a new Web resource to address global drinking water crisis
3. St. Petersburg: Candlelight Vigil to Raise Awareness of Florida HIV/AIDS Crisis, Honor Lives Lost
4. Isis Acquires Symphony GenIsis
5. New Denver Area Program Developed For Teens in Crisis
6. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
7. March of Dimes NICU Family Support(R) Programs Give Wisconsin Families Comfort and Information during a Crisis
8. March of Dimes NICU Family Support(R) Programs Give Florida Families Comfort and Information During a Crisis
9. Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
10. Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
11. Survey of Iowa Voters Reveals Surprising Results and Attitudes Toward Americas Health Care Crisis
Post Your Comments:
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ... , ... Jobs in hospital medical laboratories and in the imaging field lead ... Aureus Medical Group . These fields, as well as travel nursing, ... healthcare jobs through the company’s website, , The leading healthcare staffing ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Advanced Wound Care Market by Type (Dressings, ... End User (In-Patient Facility, Out-Patient Facility), and Geography - ... --> --> ... description, definition and forecast of the global advanced wound ...
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology: